Kristen Drejer, PhD

CHAIRWOMAN

Kirsten Drejer has a long standing experience as a successful biotech entrepreneur, having co-founded Symphogen A/S and served as CEO for 16 years. During that time, Symphogen grew from a start-up to one of the most innovative and successful clinical-stage biotechs in Europe. Dr. Drejer now serves on the boards of Zealand Pharma, BioPorto, Bioneer, Antaq Therapeutics among others.

Jeppe Øvli Øvlesen, MBA

DIRECTOR

Jeppe Øvlesen is an experienced biotech entrepreneur and has been involved as founder/CEO/Chairman in a string of successful companies including Action Pharma, CLC Bio, Cetrea, ChemoMetec, Monsenso, PNN Medical, and TXP Pharma.

Mr. Øvlesen is co-founder and presently serves as CEO of SynAct Pharma, which is listed on Nasdaq Stockholm.

Henrik Stage, MS

DIRECTOR

Henrik Stage has held roles such as VP, CFO, and CEO in a number of successful international corporations, including Carlsberg Breweries, Hempel Intl, and Santaris Pharma. At Santaris Mr. Stage served as CEO and CFO and closed partnerships with Pfizer, Wyeth, Shire, GlaxoSmithKline and managed the sale and asset transfer to Roche. Currently Mr. Stage serves as CFO at RhoVac and SynAct Pharma.

Sven Jacobson, MBA

DIRECTOR

Sven Jacobson is a life science entrepreneur. He has co-founded and serves as CEO of Woolsey Pharmaceuticals, a privately held, clinical stage pharmaceutical company.

Previously, Mr. Jacobson co-founded and served on the board of Access Scientific, Cure Therapeutics and St. Camillus Medical and is currently a Director of the Board of Critical Diagnostics and a Partner at Carrot Capital Healthcare Ventures

Thomas Feldthus, MBA

DIRECTOR

Thomas Feldthus has extensive management experience in the biotech industry. He is co-founder of Saniona, Scandion Oncology, Initiator Pharma, Symphogen, Ataxion and Leukotech. 

Previously, Mr. Feldthus served as vVD and CFO of Saniona. Prior to that he was CFO of Symphogen, Corporate Development Manager at Novo Nordisk and Investment Associate at Novo A/S. He currently serves on the board of Scandion Oncology.

Kristen Drejer, PhD

CHAIRMAN

Kirsten Drejer has a long standing experience as a successful biotech entrepreneur, having co-founded Symphogen A/S and served as CEO for 16 years.

During that time, Symphogen grew from a start-up to one of the most innovative and successful clinical-stage biotechs in Europe. Dr. Drejer now serves on the boards of Zealand Pharma, BioPorto, Bioneer, Antaq Therapeutics among others.

Jeppe Øvli Øvlesen, MBA

DIRECTOR

Jeppe Øvlesen is an experienced biotech entrepreneur and has been involved as founder/CEO/Chairman in a string of successful companies including Action Pharma, CLC Bio, Cetrea, ChemoMetec, Monsenso, PNN Medical, and TXP Pharma.

Mr. Øvlesen is co-founder and presently serves as CEO of SynAct Pharma, which is listed on the Swedish small-cap exchange Aktietorget.

Henrik Stage, MS

DIRECTOR

Henrik Stage has held roles such as VP, CFO, and CEO in a number of successful international corporations, including Carlsberg Breweries, Hempel Intl, and Santaris Pharma.

At Santaris Mr. Stage served as CEO and CFO and closed partnerships with Pfizer, Wyeth, Shire, GlaxoSmithKline and managed the sale and asset transfer to Roche. Currently Mr. Stage serves as CFO at RhoVac and SynAct Pharma.

Thomas Feldthus, MBA

DIRECTOR

Thomas Feldthus has extensive management experience in the biotech industry. He is co-founder of Saniona, Scandion Oncology, Initiator Pharma, Symphogen, Ataxion and Leukotech.

Previously, Mr. Feldthus served as vVD and CFO of Saniona. Prior to that he was CFO of Symphogen, Corporate Development Manager at Novo Nordisk and Investment Associate at Novo A/S. He currently serves on the board of Scandion Oncology.

Sven Jacobson, MBA

DIRECTOR

Sven Jacobson is a life science entrepreneur. He has co-founded and serves as CEO of Woolsey Pharmaceuticals, a privately held, clinical stage pharmaceutical company. .

Previously, Mr. Jacobson co-founded and served on the board of Access Scientific, Cure Therapeutics and St. Camillus Medical and is currently a Director of the Board of Critical Diagnostics and a Partner at Carrot Capital Healthcare Ventures